122 related articles for article (PubMed ID: 31260421)
1. Two cases of pneumonitis induced by targeted therapy.
Lafabregue E; Arnault JP; Auquier M; Magois E; Chaby G; Lok C
Melanoma Res; 2019 Aug; 29(4):441-443. PubMed ID: 31260421
[TBL] [Abstract][Full Text] [Related]
2. [Cobimetinib/vemurafenib-associated bilateral serous retinopathy: a case report].
Kastl G
Ophthalmologe; 2019 Aug; 116(8):785-788. PubMed ID: 30357465
[TBL] [Abstract][Full Text] [Related]
3. [Vemurafenib-induced radiation recall dermatitis].
Greliak A; Le Guern A; Bataille M; Lebas D; Wiart T; Modiano P
Ann Dermatol Venereol; 2019 May; 146(5):382-384. PubMed ID: 30981540
[TBL] [Abstract][Full Text] [Related]
4. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
Larkin J; Ascierto PA; Dréno B; Atkinson V; Liszkay G; Maio M; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Sovak MA; Chang I; Choong N; Hack SP; McArthur GA; Ribas A
N Engl J Med; 2014 Nov; 371(20):1867-76. PubMed ID: 25265494
[TBL] [Abstract][Full Text] [Related]
5. Cardiac toxicity of combined vemurafenib and cobimetinib administration
.
Fiocchi R; Gori M; Taddei F; Trevisani L; Gallo M; Eleftheriou G
Int J Clin Pharmacol Ther; 2019 May; 57(5):259-263. PubMed ID: 30704555
[TBL] [Abstract][Full Text] [Related]
6. Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients.
Daud A; Gill J; Kamra S; Chen L; Ahuja A
J Hematol Oncol; 2017 Jan; 10(1):3. PubMed ID: 28052762
[TBL] [Abstract][Full Text] [Related]
7. Drug reaction with eosinophilia and systemic symptoms syndrome induced by combination of vemurafenib and cobimetinib in melanoma: A series of 11 cases.
Brégeon B; Bernier C; Josselin N; Peuvrel L; Le Moigne M; Saint-Jean M; Quéreux G
J Am Acad Dermatol; 2019 Feb; 80(2):558-562. PubMed ID: 30081108
[No Abstract] [Full Text] [Related]
8. Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study.
Dréno B; Ribas A; Larkin J; Ascierto PA; Hauschild A; Thomas L; Grob JJ; Koralek DO; Rooney I; Hsu JJ; McKenna EF; McArthur GA
Ann Oncol; 2017 May; 28(5):1137-1144. PubMed ID: 28444112
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature.
van Berge Henegouwen JM; van der Wijngaart H; Zeverijn LJ; Hoes LR; Meertens M; Huitema ADR; Devriese LA; Labots M; Verheul HMW; Voest EE; Gelderblom H
Cancer Chemother Pharmacol; 2022 Jul; 90(1):97-104. PubMed ID: 35598186
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series.
Naqash AR; File DM; Ziemer CM; Whang YE; Landman P; Googe PB; Collichio FA
J Immunother Cancer; 2019 Jan; 7(1):4. PubMed ID: 30621779
[TBL] [Abstract][Full Text] [Related]
11. Effect of early adverse events on response and survival outcomes of advanced melanoma patients treated with vemurafenib or vemurafenib plus cobimetinib: A pooled analysis of clinical trial data.
Hopkins AM; Van Dyk M; Rowland A; Sorich MJ
Pigment Cell Melanoma Res; 2019 Jul; 32(4):576-583. PubMed ID: 30758912
[TBL] [Abstract][Full Text] [Related]
12. MEK Retinopathy. Clinical case reports.
Rocha Cabrera P; Quijada Fumero E; Losada Castillo MJ; Abreu Reyes JA; Lorenzo Morales J
Arch Soc Esp Oftalmol (Engl Ed); 2018 Jan; 93(1):42-46. PubMed ID: 28506716
[TBL] [Abstract][Full Text] [Related]
13. Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma.
Daud A; Tsai K
Oncologist; 2017 Jul; 22(7):823-833. PubMed ID: 28526719
[TBL] [Abstract][Full Text] [Related]
14. Gene Expression Profiling in
Wongchenko MJ; McArthur GA; Dréno B; Larkin J; Ascierto PA; Sosman J; Andries L; Kockx M; Hurst SD; Caro I; Rooney I; Hegde PS; Molinero L; Yue H; Chang I; Amler L; Yan Y; Ribas A
Clin Cancer Res; 2017 Sep; 23(17):5238-5245. PubMed ID: 28536307
[No Abstract] [Full Text] [Related]
15. The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma.
Amaral T; Nouri N; Garbe C
Expert Rev Anticancer Ther; 2016 Jul; 16(7):705-15. PubMed ID: 27219630
[TBL] [Abstract][Full Text] [Related]
16. Atypical systemic sarcoid-like granulomatosis in two patients treated with BRAF and MEK inhibitors.
Assan F; Schlemmer F; Assie JB; Mahevas M; Sustronck P; Ortonne N; Velter C; Fardet L; Zehou O
Eur J Dermatol; 2019 Oct; 29(5):556-557. PubMed ID: 31649010
[No Abstract] [Full Text] [Related]
17. Focal necrotizing myopathy with 'dropped-head syndrome' induced by cobimetinib in metastatic melanoma.
Gauci ML; Laly P; Leonard-Louis S; Behin A; Gottlieb J; Madelaine-Chambrin I; Baroudjian B; Da-Meda L; Mourah S; Battistella M; Basset-Seguin N; Bagot M; Pages C; Vercellino L; Maisonobe T; Lebbé C
Melanoma Res; 2017 Oct; 27(5):511-515. PubMed ID: 28692456
[TBL] [Abstract][Full Text] [Related]
18. Erythema multiforme-like rash upon anti-melanoma therapy with BRAF and MEK inhibitors.
Grän F; Goebeler M; Gesierich A
Eur J Dermatol; 2019 Feb; 29(1):107-108. PubMed ID: 30998207
[No Abstract] [Full Text] [Related]
19. Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study.
van der Hiel B; Haanen JBAG; Stokkel MPM; Peeper DS; Jimenez CR; Beijnen JH; van de Wiel BA; Boellaard R; van den Eertwegh AJM;
BMC Cancer; 2017 Sep; 17(1):649. PubMed ID: 28915798
[TBL] [Abstract][Full Text] [Related]
20. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.
Sanlorenzo M; Choudhry A; Vujic I; Posch C; Chong K; Johnston K; Meier M; Osella-Abate S; Quaglino P; Daud A; Algazi A; Rappersberger K; Ortiz-Urda S
J Am Acad Dermatol; 2014 Dec; 71(6):1102-1109.e1. PubMed ID: 25440439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]